Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer: Results of west Japan oncology group (WJOG) study 3906L

Journal of Thoracic Oncology

Volumn 8, Issue 6, 2013, Pages 753-758

  Kogure, Yoshihito ^a   Ando, Masahiko ^b   Saka, Hideo ^a   Chiba, Yasutaka ^c   Yamamoto, Nobuyuki ^d   Asami, Kazuhiro ^e   Hirashima, Tomonori ^f   Seto, Takashi ^g   Nagase, Seisuke ^h   Otsuka, Kojiro ⁱ   Yanagihara, Kazuhiro ^j   Takeda, Koji ^k   Okamoto, Isamu ^c   Aoki, Takuya ^l   Takayama, Koichi ^m   Yamasaki, Masahiro ⁿ   Kudoh, Shinzo ^o   Katakami, Nobuyuki ^p   Miyazaki, Mikinori ^q   Nakagawa, Kazuhiko ^c  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SHIZUOKA CANCER CENTER   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^f OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

^h TOKYO MEDICAL UNIVERSITY   (Japan)

ⁱ KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^j KYOTO UNIVERSITY   (Japan)

^k OSAKA CITY GENERAL HOSPITAL   (Japan)

^l TOKAI UNIVERSITY   (Japan)

^m KYUSHU UNIVERSITY   (Japan)

ⁿ ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^o OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^p INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^q NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

more..

Author keywords

Adenocarcinoma; Histology; Non small cell lung cancer; Smoking status

Indexed keywords

GEFITINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; FEMALE; HISTOLOGY; HUMAN; JAPAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; SURVIVAL PREDICTION;

EID: 84879505257     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31828b51f5     Document Type: Article

References (23)

1. Mitsudomi T, Morita S, Yatabe Y, et al.; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
2. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naïve patients with advanced-stage NSCLC. J Clin Oncol 2008;26:3543-3551.
3. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
5. Andrea K, Helena F, Sverre S. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thoracic Oncol 2009;4:326-332.
6. Yelena YJ, Kevin M, Kark GK, et al. Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer 2010;116:670-675.
7. Toh CK, Gao F, Lim WT, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006;24:2245-2251. (Pubitemid 46630653)
8. Kawaguchi T, Takada M, Kubo A, et al. Gender, histology, and time of diagnosis are important factors for prognosis analysis of 1499 neversmokers with advanced non-small cell lung cancer in Japan. J Thorac Oncol 2010;5:1011-1017.
9. American Joint Committee on Cancer: AJCC Cancer Staging Manual, 6th Ed. New York: Springer, 2002. Pp. 167-181.
10. Feld R, Borges M, Giner V, et al. Prognostic factors in non-small cell lung cancer. Lung Cancer 1994;11:S19-S23.
11. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers - a different disease. Nat Rev Cancer 2007;7:778-790. (Pubitemid 47463669)
12. Nordquist LT, Simon GR, Cantor A, et al. Improved survival in never smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004;126:347-351. (Pubitemid 39093415)
13. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 2004;125:27-37. (Pubitemid 38114560)
14. Zell JA, Ou SH, Ziogas A, et al. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol 2005;23:8396-8405.
15. Ou SH, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009;4:1083-1093.
16. Gealy R, Zhang L, Siegfried JM, Luketich JD, Keohavong P. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev 1999;8 (4 Pt 1):297-302. (Pubitemid 29193900)
17. Hainaut P, Pfeifer GP. Patterns of p53 G->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001;22:367-374. (Pubitemid 32203813)
18. DuyKhanh P, Mark GK, Gregory JR, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006;24:1700-1704.
19. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191. (Pubitemid 41095154)
20. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009;14:253-263.
21. Yamamoto N, Nishiwaki Y, Negoro S, et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15- 32) in advanced non-small cell lung cancer patients. J Thorac Oncol 2010;5:1042-1047.
22. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-smallcell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537. (Pubitemid 41540110)
23. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.